A5003876132- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Action Observation and Synchronization
- Brain Metastases and Treatment
- Genital Health and Disease
- Psychology of Moral and Emotional Judgment
- BRCA gene mutations in cancer
- PARP inhibition in cancer therapy
- Radiomics and Machine Learning in Medical Imaging
- Neuroendocrine Tumor Research Advances
- Metabolism, Diabetes, and Cancer
- Chronic Lymphocytic Leukemia Research
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Research Studies
- Cancer therapeutics and mechanisms
- Pituitary Gland Disorders and Treatments
- Functional Brain Connectivity Studies
- Lung Cancer Treatments and Mutations
- Colorectal and Anal Carcinomas
- Optimal Experimental Design Methods
- Myasthenia Gravis and Thymoma
- Face Recognition and Perception
- Cancer Genomics and Diagnostics
MedSIR (Spain)
2022-2024
Basque Center on Cognition, Brain and Language
2020-2024
Brain (Germany)
2018
RWTH Aachen University
2017-2018
Jülich Aachen Research Alliance
2018
1001 Background: Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) in combination with ET has become a standard first-line treatment for pts endocrine-sensitive, HR[+]/HER2[-] ABC. The optimal after progression on CDK4/6i remains unknown. This study aims to determine if P maintenance an alternative improves the antitumor activity of second-line this patient population. Methods: A total 198 ABC who had disease plus (aromatase inhibitor or fulvestrant) were included. Pts eligible they...
Social skills probably emerge from the interaction between different neural processing levels. However, social neuroscience is fragmented into highly specialized, rarely cross-referenced topics. The present study attempts a systematic reconciliation by deriving brain definition activity meta-analyses on social-cognitive capacities. was characterized meta-analytic connectivity modeling evaluating coactivation in task-focused states and physiological fluctuations correlations task-free states....
LBA506 Background: PHERGain is assessing the feasibility of a CT-free treatment based on dual HER2 blockade with trastuzumab and pertuzumab (HP) in patients (pts) HER2[+] EBC using PET-based, pathologic complete response (pCR)-adapted strategy. In an earlier analysis this study, total 227 (79.7%) 285 pts included group B were PET-responder (RX), whom 86 (37.9%, 95% CI, 31.6 to 44.5; p<0.0001) achieved pCR, reaching first primary endpoint (Perez-Garcia JM, Lancet Oncol 2021). Methods:...
Abstract Background: Leptomeningeal carcinomatosis (LMC) occurs in approximately 5-15% of patients (pts) with advanced breast cancer (ABC) and is associated poor survival a significant reduction quality life. The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) has shown remarkable intracranial extracranial activity, leading to its widespread clinical use. DEBBRAH evaluating the efficacy safety T-DXd pts HER2[+] HER2-low ABC history brain metastases (BM) and/or LMC. Here, we report...
Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin prevent or reduce hyperglycaemia occurrence in patients with HR+/HER2-/
Abstract BACKGROUND Triple-negative breast cancer (TNBC) is an aggressive tumor characterized by poor outcomes and new treatment strategies are urgently required. The programmed cell death-ligand 1 (PD-L1) antibody (Ab) atezolizumab (ATZ) combined with first-line (1L) nab-paclitaxel (nab-PTX) approved in multiple countries for the of PD-L1-positive patients (pts) advanced TNBC (aTNBC) based on a significant improvement progression-free survival (PFS) numerically higher clinically meaningful...
PURPOSE Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus endocrine therapy (ET) represents the standard first-line treatment for patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HER2-negative) advanced breast cancer (ABC). However, there is no definitive consensus on preferred second-line option. The PALMIRA trial investigated whether palbociclib rechallenge an alternative ET would improve antitumor activity in progressing after a...
Abstract Background: Detection of MRD through ctDNA has been consistently associated with high risk relapse. Longitudinal evaluation to monitor is a minimally invasive tool that may predict disease recurrence and treatment response. MiRaDor aims improve the clinical utility understand its applicability in high-risk, HR+/HER2- EBC patients (pts). Trial Design: (NCT05708235) multicenter, open-label, non-comparative, phase II trial. Selection criteria include pts: a) at relapse, b) on adjuvant...
1098 Background: New therapies are urgently needed for aTNBC. The PI3K/AKT/mTOR pathway and its link to chemoresistance warrant further investigation in pre-treated TNBC patients. pan-AKT inhibitor IPA, alone or combined, has shown promise treating advanced solid tumors. This study assessed the toxicity efficacy of IPA with non-taxane CT aTNBC pts. Methods: PATHFINDER (NCT04464174) is a multicenter, open-label, non-comparative, phase IIa trial safety run-in phase. Taxane-pretreated pts 1-2...
Niraparib is a potent, highly selective, PARP 1/2 inhibitor with clinical activity for patients (pts) ovarian and breast cancer that harbor germline BRCA mutations (gBRCAm). LUZERN evaluated the efficacy safety of niraparib plus AI AI-resistant HR+/HER2- advanced (ABC) pts gBRCAm or homologous recombinant deficient (HRD)/non-gBRCAm. (NCT04240106) was an open-label, single-arm, two-cohort, Simon Two-Stage, phase II trial. Pts ABC (cohort A) HRD/non-gBRCAm B) who had received ≤1 line...
Abstract The DEBBRAH study (NCT04420598) evaluated the efficacy and safety of trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, in patients with HER2-positive HER2-low ABC brain metastases (BM) and/or LMC. Forty-one aged ≥18 years were enrolled 5 cohorts: (1) non-progressing BM after radiotherapy surgery (n=8); (2) or asymptomatic untreated (n=10); (3) progressing local treatment (n=9); (4) (n=7); (5) pathologically confirmed LMC (n=7). Patients received 5.4 mg/kg T-DXd...
5043 Background: PSqCC is a rare tumor with poor prognosis. The standard of care for advanced disease (AD) has been palliative platinum-based chemotherapy (CT). Most patients (pts) have high levels programmed death-ligand 1 (PD-L1). ORPHEUS evaluated the efficacy and safety Rf –a PD-1 antagonist– in pts unresectable locally or metastatic PSqCC. Methods: (NCT04231981) an international, multicenter, open-label, single-arm phase II trial. study enrolled aged ≥18 years who had not received any...
De-escalation trials in oncology evaluate therapies that aim to improve the quality of life patients with low-risk cancer by avoiding overtreatment. Non-inferiority randomized are commonly used investigate de-intensified regimens similar efficacy standard but fewer adverse effects (ESMO evidence tier A). In cases where it is not feasible recruit number needed for a trial, single-arm prospective studies hypothesis non-inferiority can be conducted as an alternative. Single-arm also novel...
Background: Luminal advanced breast cancer (ABC) patients eventually progress on endocrine therapy. REVERT aimed to explore whether eribulin could restore sensitivity in a randomized, non-comparative phase II trial. Methods: Aromatase inhibitor (AI)-resistant with luminal ABC were randomized 1:1 receive +/− AI. Patients stratified by prior cyclin-dependent kinases 4/6 (CDK4/6i) treatment. The primary endpoint was an investigator-assessed overall response rate (ORR) according RECIST version...
Understanding how the human brain maps different dimensions of social conceptualizations remains a key unresolved issue. We performed functional magnetic resonance imaging (MRI) study in which participants were exposed to audio definitions personality traits and asked simulate experiences associated with concepts. Half concepts affective (e.g. empathetic), other half non-affective intelligent). Orthogonally, highly likable sincere) socially undesirable liar). Behaviourally, we observed that...
To evaluate olaparib in advanced triple negative breast cancer (TNBC) patients with homologous recombination deficiency (HRD) and no germline BRCA1/2 mutations (gBRCA1/2mut).